2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 840

Time Trends in Incidence and Mortality of Systemic Sclerosis in Denmark from 1995-2011: A Nationwide Cohort Study
Abstract Number: 2711

Tissue-Resident IL-23 Responsive Innate T Cells in Mice Comprise Tcrαβ+ and TCRγδ+ Subsets with Overlapping Function
Abstract Number: 2057

TLR-7-Mediated Lupus Nephritis Flares Are Independent of Type I Interferon Signaling
Abstract Number: 2526

TNF Blocker Concentrations or Detection of Antibodies Against Anti-TNF before a Tapering Process Are Not Predictive to Relapse
Abstract Number: 1922

TNF-α and IL-6 Induced Upregulation of CCR5 and CXCR3 Participate in Vδ2 Chemotaxis in RA
Abstract Number: 1682

Tnfα Inhibitors Are Associated with Reduced Progression of Carotid Atherosclerotic Plaques By Ultrasound and an Improvement in Aortic Arch Vascular Inflammation By 18-FDG PET/CT in Psoriasis and Psoriatic Arthritis Patients – a Prospective Study from Two Cohorts
Abstract Number: 2499

Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis
Abstract Number: 977

Tocilizumab As an Add-on Therapy to Glucocorticoids during the First 3 Months of Treatment of Giant Cell Arteritis: Results of a French Multicenter Prospective Open-Label Study
Abstract Number: 3183

Tocilizumab for the Treatment of Giant Cell Arteritis – MR-Angiography Results from the First Randomized Placebo-Controlled Trial
Abstract Number: 1336

Tocilizumab for Uveitic Cystoid Macular Edema Refractory to Other Synthetic and Biological Immunosuppressive Drugs. Multicenter Study of 25 Patients
Abstract Number: 955

Tocilizumab Infusion Intervals Can be Extended to 5 or 6 Weeks in RA Patients Who Sustained Low Disease Activity By 4 Weeks Interval of Tocilizumab Infusion
Abstract Number: 2502

Tocilizumab Therapy Reduces Corrected QT Interval in Patients with Rheumatoid Arthritis without Cardiac Symptoms
Abstract Number: 2580

Tofacitinib Do Not Get Worse Subclinical Atherosclerosis Despite up-Regulating Serum Cholesterol in Methotrexate-Resistant Active Rheumatoid Arthritis Patients
Abstract Number: 2600

Tofacitinib Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas
Abstract Number: 1438

Tofacitinib Restores Reverse Cholesterol Transport Inhibition Induced By Inflammation. Understanding the Lipid Paradox

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].